Phenotypic screening strategies for neurodegenerative diseases: A pathway to discover novel drug candidates and potential disease targets or mechanisms

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 6, 2010, Pages 693-700

  Pruss, R M ^a  

^a Trophos   (France)

Author keywords

cell based assays; chemical genetics; drug discovery; Huntington's disease; Motor neuron disease; phenotypic screening

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIAMORPHINE; DIAZEPAM; DILTIAZEM; EFLORNITHINE; GLITAZONE DERIVATIVE; HUNTINGTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; METFORMIN; NATURAL PRODUCT; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLESOXIME; OXIME DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; QUININE; SILDENAFIL; TICLOPIDINE; UNCLASSIFIED DRUG; VERAPAMIL; ZOLPIDEM;

ARTICLE; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUNTINGTON CHOREA; MOTONEURON; MOTOR NEURON DISEASE; NERVE CELL; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; SCREENING; STRESS; STRIATE CORTEX; STRUCTURE ACTIVITY RELATION; SURVIVAL;

EID: 78649255346     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710793237377     Document Type: Article

References (50)

1. Leavitt, B.R.; Guttman, J.A.; Hodgson, J.G.; Kimel, G.H.; Singaraja, R.; Vogl, A.W.; Hayden, M.R. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am. J. Hum. Genet., 2001, 68(2), 313-324.
2. Van Raamsdonk, J.M.; Pearson, J.; Rogers, D.A.; Bissada, N.; Vogl, A.W.; Hayden, M.R.; Leavitt, B.R. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 2005, 14(10), 1379-1392.
3. Ludolph, A.C.; Sperfeld, A.D. Preclinical trials--an update on translational research in ALS. Neurodegener. Dis., 2005, 2(3-4), 215-219.
4. Ludolph, A.C.; Bendotti, C.; Blaugrund, E.; Hengerer, B.; Löffler, J.P.; Martin, J.; Meininger, V.; Meyer, T.; Moussaoui, S.; Robberecht, W.; Scott, S.; Silani, V.; Van Den Berg, L.H.; ENMC Group for the Establishment of Guidelines for the Conduct of Preclinical and Proof of Concept Studies in ALS/MND Models. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph. Lateral. Scler., 2007, 8(4), 217-223.
5. Turner, B.J.; Talbot, K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog. Neurobiol., 2008, 85(1), 94-134.
6. Scott, S.; Kranz, J.E.; Cole, J.; Lincecum, J.M.; Thompson, K.; Kelly, N.; Bostrom, A.; Theodoss, J.; Al-Nakhala, B.M.; Vieira, F.G.; Ramasubbu, J.; Heywood, J.A. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph. Lateral. Scler., 2008, 9(1), 4-15.
7. Garfield, S. Mauve: How One Man Invented a Color and changed the World. Faber & Faber: London, 2000.
8. Henderson, C.E.; Bloch-Gallego, E.; Camu, W. Purified embryonic motoneurons. In Nerve Cell Culture: A Practical Approach; Cohen, J.; Wilkin, G., Eds.; Oxford UP: London, 1995; pp. 69-81.
9. Dupuis, L.; Loeffler, J.P. Neuromuscular junction destruction during amyotrophic lateral sclerosis: insights from transgenic models. Curr. Opin. Pharmacol., 2009, 9(3), 341-346.
10. Dupuis, L.; Loeffler, J.P. Amyotrophic lateral sclerosis: role of energy deficiency in neuromuscular junction dismantlement. Med. Sci. (Paris), 2008, 24(12), 1077-1082.
11. Dupuis, L.; Gonzalez de Aguilar, J.L.; Echaniz-Laguna, A.; Eschbach, J.; Rene, F.; Oudart, H.; Halter, B.; Huze, C.; Schaeffer, L.; Bouillaud, F.; Loeffler, J.P. Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons. PLoS One, 2009, 4(4), e5390.
12. Rothstein, J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol., 2009, 65(Suppl 1), S3- S9.
13. Sendtner, M.; Kreutzberg, G.W.; Thoenen, H. Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy. Nature, 1990, 345(6274), 440-441.
14. Bordet, T.; Lesbordes, J.C.; Rouhani, S.; Castelnau-Ptakhine, L.; Schmalbruch, H.; Haase, G.; Kahn, A. Protective effects of cardiotrophin-1 adenoviral gene transfer on neuromuscular degeneration in transgenic ALS mice. Hum. Mol. Genet., 2001, 10(18), 1925-1933.
15. Wang, L.J.; Lu, Y.Y.; Muramatsu, S.; Ikeguchi, K.; Fujimoto, K.; Okada, T.; Mizukami, H.; Matsushita, T.; Hanazono, Y.; Kume, A.; Nagatsu, T.; Ozawa, K.; Nakano, I. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurosci., 2002, 22(16), 6920-6928.
16. Lesbordes, J. C.; Cifuentes-Diaz, C.; Miroglio, A.; Joshi, V.; Bordet, T.; Kahn, A.; Melki, J. Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy. Hum. Mol. Genet., 2003, 12(11), 1233-1239.
17. Bordet, T.; Pruss, R.; Henderson, C. E. Screening for ALS drugs. In: Amyotrophic Lateral Sclerosis; Mitsumoto, H.; Przedborski, S.; Gordon, P.H., Eds.; Taylor & Francis Group: New York, 2006, pp. 551-582.
18. Bordet, T.; Buisson, B.; Michaud, M.; Drouot, C.; Galea, P.; Delaage, P.; Akentieva, N. P.; Evers, A.S.; Covey, D.F.; Ostuni, M.A.; Lacapere, J.J.; Massaad, C.; Schumacher, M.; Steidl, E-M.; Maux, D.; Delaage, M.; Henderson, C.E.; Pruss, R.M. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther., 2007, 322(2), 709-770.
19. Bordet, T.; Buisson, B.; Michaud, M.; Abitbol, J.L.; Marchand, F.; Grist, J.; Andriambeloson, E.; Malcangio, M.; Pruss, R.M. Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy. J. Pharmacol. Exp. Ther., 2008, 326(2), 623-632.
20. Xiao, W.H.; Zheng, F.Y.; Bennett, G.J.; Bordet, T.; Pruss, R.M. Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. Pain, 2009, 147(1-3), 202-209.
21. Bordet, T.; Berna, P.; Abitbol, J-L.; and Pruss, R.M. Olesoxime (TRO19622): a Novel Mitochondrial-Targeted Neuroprotective Compound. Pharmaceuticals, 2010, 3, 345-368.
22. Mattson, M.P.; Kroemer, G. Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol. Med., 2003, 9(5),196-205.
23. Flatters, S.J.; Bennett, G.J. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain, 2006, 122(3), 245-257.
24. Chaturvedi, R.K.; Beal, M.F. Mitochondrial approaches for neuroprotection. Ann. N Y Acad. Sci., 2008, 1147, 395-412.
25. Javadov, S.; Karmazyn, M.; Escobales, N. Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J. Pharmacol. Exp. Ther., 2009, 330(3), 670-678.
26. Cattaneo, E.; Zuccato, C.; Tartari, M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci., 2002, 6(12), 919-930.
27. Saudou, F.; Finkbeiner, S.; Devys, D.; Greenberg, M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell, 1998, 95(1), 55-66.
28. Humbert, S.; Bryson, E.A.; Cordelières, F.P.; Connors, N.C.; Datta, S.R.; Finkbeiner, S.; Greenberg, M.E. Saudou, F. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell, 2002, 2(6), 831-837.
29. Dunah, A.W.; Jeong, H.; Griffin, A.; Kim, Y.M.; Standaert, D.G.; Hersch, S.M.; Mouradian, M.M.; Young, A.B.; Tanese, N.; Krainc, D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science, 2002, 296(5576), 2238-2243.
30. Arrasate, M.; Mitra, S.; Schweitzer, E.S.; Segal, M.R.; Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature, 2004, 431(7010), 805-810.
31. Zhai, W.; Jeong, H.; Cui, L.; Krainc, D.; Tjian, R. In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell, 2005, 123(7), 1241-1253.
32. Valenza, M.; Rigamonti, D.; Goffredo, D.; Zuccato, C.; Fenu, S.; Jamot, L.; Strand, A.; Tarditi, A.; Woodman, B.; Racchi, M.; Mariotti, C.; Di Donato, S.; Corsini, A.; Bates, G.; Pruss, R.; Olson, J. M.; Sipione, S.; Tartari, M.; Cattaneo, E. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J. Neurosci., 2005, 25(43), 9932-9939.
33. Stockwell, B.R. Exploring biology with small organic molecules. Nature, 2004, 432(7019), 846-854.
34. Vanderluit, J.L.; McPhail, L.T.; Fernandes, K.J.; Kobayashi, N.R.; Tetzlaff, W. In vivo application of mitochondrial pore inhibitors blocks the induction of apoptosis in axotomized neonatal facial motoneurons. Cell Death Differ., 2003, 10(9), 969-976.
35. Wong, P.C.; Pardo, C.A.; Borchelt, D.R.; Lee, M.K.; Copeland, N.G.; Jenkins, N.A.; Sisodia, S.S.; Cleveland, D.W.; Price, D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron, 1995, 14(6), 1105-1116.
36. Kong, J.; Xu, Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci., 1998, 18(9), 3241-3250.
37. 2+] elevations in mouse motor terminals: comparison of wild-type with SOD1-G93A. J. Physiol., 2003, 549(Pt 3), 719-728.
38. Kirkinezos, I.G.; Hernandez, D.; Bradley, W.G.; Moraes, C.T. An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment. J. Neurochem., 2004, 88(4), 821-826.
39. Martin, L.J.; Gertz, B.; Pan, Y.; Price, A.C.; Molkentin, J.D.; Chang, Q. The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice. Exp. Neurol., 2009, 218(2), 333-346.
40. Hersch, S.M.; Ferrante, R. Translating therapies for Huntington's disease from genetic animal models to clinical trials. NeuroRx, 2004, 1(3), 298-306.
41. Wang, L.H.; Qin, Z.H. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies. Acta Pharmacol. Sin., 2006, 27(10), 1287-1302.
42. Ramaswamy, S.; McBride, J.L.; Kordower, J.H. Animal models of Huntington's disease. ILAR J., 2007, 48(4), 356-373.
43. Brown M.S.; Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science, 1986, 232(4746), 34-47.
44. Endo, A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res., 1992, 33(11), 1569-1582.
45. Patlak, M. New weapons to treat an ancient disease: treating diabetes. FASEB J., 2002, 16(14), 1853.
46. Adams, S.S. The propionic acids: a personal perspective. J. Clin. Pharmacol., 1992, 32(4), 317-323.
47. Hollopeter, G.; Jantzen, H.M.; Vincent, D.; Li, G.; England, L.; Ramakrishnan, V.; Yang, RB.; Nurden, P.; Nurden, A.; Julius, D.; Conley P.B. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature, 2001, 409(6817), 202-207.
48. Dolphin, A. A short history of calcium channels. Br. J. Pharmacol., 2006, 147(S1), S56-S62.
49. Puia, G.; Santi, M.R.; Vicini, S.; Pritchett, D.B.; Seeburg, P.H.; Costa, E. Differences in the negative allosteric modulation of gamma-aminobutyric acid receptors elicited by 4'-chlorodiazepam and by a beta-carboline-3-carboxylate ester: a study with natural and reconstituted receptors. Proc. Natl. Acad. Sci. USA, 1989, 86(18), 7275-7279.
50. Graham, D.; Faure, C.; Besnard, F.; Langer, S.Z. Pharmacological profile of benzodiazepine site ligands with recombinant GABAA receptor subtypes. Eur. Neuropsychopharmacol., 1996, 6(2), 119-125.